drug_type
RELEVANT_DRUG
intervention_type
Biologic cancer vaccine
drug_description
Therapeutic cancer vaccine designed to elicit MUC1-specific CD4+/CD8+ T-cell and antibody responses against tumor-associated MUC1.
nci_thesaurus_concept_id
C53290
nci_thesaurus_preferred_term
MUC-1 Peptide Vaccine
nci_thesaurus_definition
A cancer vaccine comprised of a synthetic peptide derived from the mucin 1 (MUC1) antigen with potential antineoplastic activity. Upon administration, MUC1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC1 antigen, resulting in decreased tumor growth. Overexpressed on many tumor cells, MUC1 antigen, a mammary-type apomucin, is a high-molecular-weight transmembrane glycoprotein.
drug_mesh_term
Cancer Vaccines
drug_category
PEPTIDE VACCINE
drug_class
Vaccine
drug_delivery_route
Not specified
drug_mechanism_of_action
Synthetic MUC1-derived peptide that is taken up by antigen-presenting cells and presented on MHC I/II to elicit MUC1-specific CD8+ cytotoxic T cells, CD4+ helper T cells, and antibodies, leading to immune-mediated killing of MUC1-expressing tumor cells and reduced tumor growth.
drug_name
MUC1 peptide vaccine
nct_id_drug_ref
NCT06218303